Drug Trial Radar · NCT07089706
A Study to Evaluate the Immunogenicity and Safety of mRNA-1283 COVID-19 Variant-containing Formulations
Last checked: Nov 20, 2026Latest source record: Jul 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
832
Actual
Start
Jul 21, 2025
Primary completion
Jun 16, 2026
Study completion Jun 16, 2026
Sponsor
- Lead sponsor
- ModernaTX, Inc.Moderna (MRNA)
- Sponsor type
- Industry
- First posted
- Jul 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the immunogenicity and safety of the recommended variant-containing formulations of mRNA-1283 COVID-19 vaccine (mNEXSPIKE®) within the current epidemiological environment.
Conditions
- COVID-19
Interventions
mRNA-1283.251 Variant-containing FormulationBiological
Sterile liquid for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Subprotocol 1: Part A - Geometric Mean (GM) Value of Neutralizing Antibody (nAb) Against Vaccine-matched COVID-19 VariantsTime frame: Day 29
- Subprotocol 1: Part A - Geometric Mean Fold Rise (GMFR) of nAb Against Vaccine-matched COVID-19 VariantsTime frame: Baseline to Day 29
- Subprotocol 1: Part B - GMFR of nAb Against Vaccine-matched COVID-19 VariantsTime frame: Baseline to Day 29
- Subprotocol 1: Part A - Seroresponse Rate (SRR) of nAb Against Vaccine-matched COVID-19 VariantsTime frame: Baseline to Day 29
Locations
5 sites in 1 country. Site status is shown where the registry gives one.
DelRicht Research-Atlanta
Atlanta, Georgia
DelRicht Research-Baton Rouge
Baton Rouge, Louisiana
DelRicht Research-New Orleans
New Orleans, Louisiana
DelRicht Research-Gulfport
Gulfport, Mississippi
DelRicht Research-Tulsa
Tulsa, Oklahoma
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.